MARKET

ORMP

ORMP

Oramed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.69
+0.11
+1.22%
Opening 10:05 01/27 EST
OPEN
8.64
PREV CLOSE
8.58
HIGH
8.83
LOW
8.56
VOLUME
37.25K
TURNOVER
--
52 WEEK HIGH
31.54
52 WEEK LOW
5.75
MARKET CAP
330.78M
P/E (TTM)
-11.3337
1D
5D
1M
3M
1Y
5Y
Oramed Issues Annual Message to Shareholders
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. To see a vide...
PR Newswire · 01/12 13:45
BRIEF-Oramed Granted Key European Patent For Platform Technology In Oral Delivery Of Proteins
reuters.com · 01/05 12:49
Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the European Patent Office has granted the Company a patent titled "Protea...
PR Newswire · 01/05 12:30
BRIEF-Mymd Pharmaceuticals Investment Company Oravax Medical Signs Cooperation And Purchase Agreement For Initial Pre-Purchase Of 10 Million Doses Of Oral Covid-19 Vaccine To Be Commercialized In Southeast Asia
reuters.com · 12/29/2021 14:23
MyMD Pharmaceuticals Highlights Investment Company Oravax Medical's Cooperation And Purchase Agreement For Initial Pre-Purchase Of 10M Doses Of Oral COVID-19 Vaccine To Be Commercialized In Southeast Asia
In addition to pre-purchase order, parties have agreed to negotiate potential follow-on orders that could be significant MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a
Benzinga · 12/29/2021 14:16
Oramed's subsidiary inks purchase deal for 10M doses of oral COVID-19 vaccines in Southeast Asia
Oramed Pharmaceuticals' (NASDAQ:ORMP) subsidiary, Oravax Medical, has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company to pre-purchase Oravax's oral COVID-19 vaccine, currently in
Seekingalpha · 12/29/2021 11:29
Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh
Oramed Pharmaceuticals Inc. said Wednesday its Oravax Medical subsidiary has signed an agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Co. to pre-purchase 10 million doses of Oravax's oral COVID-19 vaccines in development. The drug m...
marketwatch.com · 12/29/2021 11:14
BRIEF-Oramed Subsidiary Oravax Medical Signs Deal For An Initial Pre-Purchase Of 10 Mln Doses Of Oral COVID-19 Vaccines With Tan Thanh Holdings To Commercialize In Southeast Asia
reuters.com · 12/29/2021 11:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ORMP. Analyze the recent business situations of Oramed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ORMP stock price target is 33.00 with a high estimate of 40.00 and a low estimate of 23.00.
High40.00
Average33.00
Low23.00
Current 8.69
EPS
Actual
Estimate
-0.18-0.14-0.09-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 103
Institutional Holdings: 5.88M
% Owned: 15.43%
Shares Outstanding: 38.09M
TypeInstitutionsShares
Increased
40
1.55M
New
26
1.11M
Decreased
13
232.18K
Sold Out
7
133.55K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.63%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Non-Executive Chairman/Independent Director
Kevin Rakin
Chief Executive Officer/President/Director
Nadav Kidron
Chief Financial Officer/Treasurer
David Silberman
Chief Operating Officer
Joshua Hexter
Chief Scientific Officer/Director
Miriam Kidron
General Counsel/Secretary
Netanel Derovan
Other
Michael Rabinowitz
Independent Director
Aviad Friedman
Independent Director
Arie Mayer
Independent Director
Leonard Sank
No Data
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Its pipeline products are ORMD-0801 Type 1, ORM-0801 Type 2 and ORMD-0901. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule. It is anticipated for use as a complementary agent to insulin injections in the treatment of Type I diabetes Mellitus (T1DM) and T2Dm disease. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM. Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which is a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. The Company's other product is ORMD-0901, an orally ingestible GLP-1 capsule.

Webull offers kinds of Oramed Pharmaceuticals, Inc. stock information, including NASDAQ:ORMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORMP stock methods without spending real money on the virtual paper trading platform.